Gain Therapeutics Q3 net loss $4.56M ($0.38/share); cash $25.7M; CEO promoted; GT-02287 Phase 1 expected mid-2023

Gain Therapeutics, Inc.

2022-Q3 EPS reported -$1.09 revenue$140,108

Net loss of $4.56M ($0.38 per share) vs $4.66M ($0.39) in Q3 2021.
Cash, equivalents, and marketable securities $25.7M, providing runway into Q2 2024.
R&D expenses $1.96M (down 21% YoY); G&A $2.79M (up 27% YoY).
Matthias Alder promoted to CEO and appointed to board of directors.
Lead Parkinson's candidate GT-02287 to commence Phase 1 trial in mid-2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Gain Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 10, 2022, Gain Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2022, and business update.

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

Gain Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-017407

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.